gemcitabine + docetaxel + radiation therapy

This investigational neoadjuvant treatment regimen combines the chemotherapy agents gemcitabine and docetaxel with concurrent radiation therapy. Gemcitabine is a pyrimidine nucleoside analog that acts as an antimetabolite, inhibiting DNA synthesis by incorporating into DNA and inhibiting ribonucleotide reductase. Docetaxel is a taxane-based chemotherapy that binds to and stabilizes microtubules, preventing their disassembly and leading to cell cycle arrest at the G2/M phase. The regimen is being investigated by Wake Forest University Health Sciences in a Phase 1 dose-escalation study (NCT04037527) for the treatment of high-grade, large (>5 cm), resectable soft tissue sarcomas of the extremities. The study aims to determine the maximum tolerated doses of the combined chemotherapy when administered weekly with concurrent radiation and to evaluate the immunological changes induced by the therapy prior to surgical resection.

Other names

Gemcitabine and Docetaxel With RadiationGem-Tax-Radiation